Cosentyx Injection
Secukinumab
150mg
NOVARTIS PHARMA STEIN AG
| Pack size | 1ml Pre-filled Syringe |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | ALPHAMED CO. (AUH) LTD. |
| Retail Price | 4026.50 AED |
Available as:
Indications
Cosentyx Injection is used for:
Indicated for, moderate-to-severe plaque psoriasis, in patients who are candidates for systemic therapy or phototherapy, indication includes, treatment for moderate-to-severe scalp psoriasis, active psoriatic arthritis, active ankylosing spondylitis
Adult Dose
Subcutaneous
Plaque psoriasis
Adult: 300 mg every week for 5 doses, followed by 300 mg every month. Each 300 mg dose is given as 2 injections of 150 mg. Review treatment if no response within 16 weeks of initial dose.
Psoriatic arthritis
Adult: 150 mg every week for 5 doses, followed by 150 mg every month, may increase to 300 mg if response is inadequate. Coexistent moderate to severe plaque psoriasis or anti-TNF? inadequate responders: 300 mg every week for 5 doses, followed by 300 mg every month. Review treatment if there is no response after 16 weeks.
Ankylosing spondylitis
Adult: 150 mg once weekly for 5 weeks, then once monthly thereafter. Review treatment if there is no response after 16 weeks.
Child Dose
Renal Dose
Administration
Powd for inj: Reconstitute 150 mg vial w/ 1 mL sterile water for inj to make a 150 mg/mL soln.
Contra Indications
Serious infections (e.g. active TB, hepatitis B, sepsis). Admin of live vaccines.
Precautions
Patient w/ history of recurrent or chronic infection, inflammatory bowel disease (e.g. Crohn’s disease). Pregnancy and lactation.
Pregnancy-Lactation
Pregnancy Category: B
Lactation: Unknown if distributed in human breast milk
Interactions
May enhance the adverse effects and diminish the therapeutic effect of live vaccines.
Adverse Effects
Side effects of Secukinumab :
>10%
Infections (28.7%)
Nasopharyngitis (11.4-12.3%)
1-10%
Diarrhea (2.6-4.1%)
URT infection (2.5-3.2%)
Rhinitis (1.4%)
Oral herpes (0.1-1.3%)
Pharyngitis (1-1.2%)
Urticaria (0.6-1.2%)
Rhinorrhea (0.3-1.2%)
Mechanism of Action
Secukinumab is a recombinant fully human IgG1/K monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines, chemokines, and mediators of tissue damage.
Note
Cosentyx 150mg Injection manufactured by NOVARTIS PHARMA STEIN AG. Its generic name is Secukinumab. Cosentyx is availble in United Arab Emirates.
Farmaco UAE drug index information on Cosentyx Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.